3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Breast Neoplasms
36
Neoplasms
7
Neoplasm Metastasis
7
Endometrial Neoplasms
7
Ovarian Neoplasms
5
Triple Negative Breast Neoplasms
4
Breast Diseases
3
Brain Neoplasms
3
Sarcoma
2
Neoplasms by Site
2
Meningioma
2
Liposarcoma
2
Glioblastoma
2
Fallopian Tube Neoplasms
2
Breast Neoplasms, Male
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Kaposi
1
Retinoblastoma
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Osteosarcoma
1
Neurofibromatosis 1
1
Neoplasm, Residual
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Interventions
Cyclophosphamide
29
fludarabine
19
Rituximab
15
fludarabine phosphate
12
Specimen Handling
8
obinutuzumab
7
Immunotherapy, Adoptive
7
Lenalidomide
6
Etoposide
6
pirtobrutinib
5
ibrutinib
5
glofitamab
5
axicabtagene ciloleucel
5
Whole-Body Irradiation
5
Mycophenolic Acid
5
venetoclax
4
polatuzumab vedotin
4
Prednisone
4
Melphalan
4
Granulocyte Colony-Stimulating Factor
4
Doxorubicin
4
Blood Component Removal
4
Biopsy
4
pembrolizumab
3
daratumumab
3
X-Rays
3
Vincristine
3
Stem Cell Transplantation
3
Interleukin-2
3
Injections
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Lymphoma, Non-Hodgkin
×
abemaciclib
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled